Search All News
Leaders in prostate cancer research and care will convene Sept. 22 for the inaugural NYC Prostate Cancer Summit, a patient-focused event co-hosted by CUIMC and NewYork-Presbyterian.
Researchers discovered a mechanism that reprograms tumor cells in patients with advanced prostate cancer, reducing their response to anti-androgen therapy.
An experimental urine test that detects genetic changes associated with prostate cancer identified 92 percent of men with elevated PSA levels who had more aggressive disease.
- March 27, 1997